Paul J. Diaz serves as the President and Chief Executive Officer at Myriad Genetics Inc., a leading personalized medicine company dedicated to advancing health and well-being through innovative genetic testing and research. With a robust background in healthcare and biotechnology, Diaz has been instrumental in steering Myriad Genetics towards significant growth and innovation. He joined the company in 2015 as a member of the board of directors before being appointed CEO in 2017. Under his leadership, Myriad has expanded its portfolio of genetic tests and enhanced its commitment to precision medicine, thereby improving patient outcomes and advancing the field of genomics. Prior to his role at Myriad Genetics, Diaz held various high-level positions in the healthcare industry. He was the President and CEO of Kindred Healthcare, one of the largest providers of post-acute care services in the United States. During his tenure at Kindred, he successfully led the company through a period of significant growth and transformation, solidifying its position as a leader in the healthcare sector. Diaz's strategic vision and leadership skills have been pivotal in his career, earning him recognition and respect within the industry. His experience in managing large-scale healthcare operations and his deep understanding of the biotechnology sector make him an invaluable asset to Myriad Genetics. As CEO of Myriad Genetics, Paul J. Diaz is responsible for overseeing the company's strategic direction, operational performance, and commitment to delivering high-quality genetic testing services. His leadership has been crucial in driving the company's mission to provide actionable genetic insights that inform healthcare decisions and improve patient care. Under his guidance, Myriad has continued to innovate and expand its offerings, including the development of new tests and the enhancement of existing ones. Diaz's dedication to advancing personalized medicine and his ability to navigate the complex landscape of genetic testing have positioned Myriad Genetics as a frontrunner in the field, ensuring its continued success and impact on global health.